151096-09-2
151096-09-2 結(jié)構(gòu)式
基本信息
莫西沙星
(4ΑS-CIS)-1-環(huán)丙基-6-氟-1,4-二氫-8-甲氧基-7-(六氫-6H-吡咯[3,4-B] 吡啶-6-基)-4-氧-3-喹啉羧酸
(1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
MAXIOFFOXACIN
(4αS-cis)-1-Cydopropyl-6-fluoro-1，4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo[3，4-b]pyridin-6-y1)-4-oxo-3-quinolinecarboxylic acid
Avdox
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
應(yīng)用領(lǐng)域
制備方法
常見問題列表
莫西沙星最常見的不良反應(yīng)包括：惡心、腹瀉、頭痛和頭暈以及心臟Q-T間期延長。
較少見的不良反應(yīng)，包括全身反應(yīng)（如過敏反應(yīng)等）、心血管系統(tǒng)反應(yīng)（如高血壓、心悸）、消化系統(tǒng)反應(yīng)（如腹痛、厭食、便秘、消化不良等）、骨骼肌肉系統(tǒng)反應(yīng)（如關(guān)節(jié)痛、肌肉痛）、神經(jīng)系統(tǒng)反應(yīng)（如激動(dòng)、焦慮、失眠、緊張、感覺異常等）、呼吸系統(tǒng)反應(yīng)（如呼吸困難）、皮膚軟組織系統(tǒng)反應(yīng)（如瘙癢、皮疹、多汗等）。
此外，莫西沙星還可能導(dǎo)致部分實(shí)驗(yàn)室檢驗(yàn)異常，如中性粒細(xì)胞減少，堿性磷酸酶、血清尿素氮、血清肌酐升高等。
1）如果口服莫西沙星，請固定在每天同一時(shí)間服藥，餐前餐后均可；如果靜脈滴注莫西沙星，請至少滴注90分鐘；
2）用藥后接觸陽光或紫外線，可能引起嚴(yán)重的光過敏，出現(xiàn)過度曬傷的癥狀，所以用藥期間請采取防曬措施；
3）莫西沙星可能引起頭暈等情況，用藥期間盡量避免駕駛等危險(xiǎn)行為；
4）用藥后可能會(huì)干擾血糖，如果糖尿病患者使用，請注意監(jiān)測血糖；
用藥后可能引發(fā)嚴(yán)重副作用，如肌腱炎、肌腱斷裂、周圍神經(jīng)病變及中樞神經(jīng)系統(tǒng)副作用，或加重重癥肌無力，如果出現(xiàn)以上副作用，請停藥并聯(lián)系醫(yī)師，避免再次用藥。
Bacterial
The in vitro activities of Moxifloxacin and Amoxicillin are compared by time-kill curve and inhibition of intracellular growth experiments by using a model of bone marrow-derived mouse macrophages infected by L. monocytogenes EGDe. Moxifloxacin acts much more rapidly, beginning to exert its effects in the first 3 h and achieving complete broth sterilization within 24 h of incubation. Moxifloxacin appears to have a protective effect against macrophage lysis, as many cells are still viable after 24 h of incubation.
Moxifloxacin (12 mg/kg; intravenous injection; once-three times per day; for 7 days; white male Wistar rats) treatment every 8 hours is accompanied by longer survival. Tissue cultures 30 hours after bacterial challenge shows considerably less bacterial overgrowth in the spleens and lungs of moxifloxacin-treated than in salinetreated animals and without being toxic.
| Animal Model: | 144 white male Wistar rats (18-22 weeks; 300-400 g) infected Stenotrophomonas maltophilia |
| Dosage: | 12 mg/kg |
| Administration: | Intravenous injection; once per day, twice per day, three times per day; for 7 days |
| Result: | Showed considerably less bacterial overgrowth in the spleens and lungs and without being toxic. |